18 May 2020: 

Public health measures implemented by Australian and New Zealand governments have been successful in controlling the spread of SARS-CoV-2, the coronavirus that causes COVID-19. This means that plans are being made in most regions to re-open schools for face to face learning.

In response to this, ASCIA has developed new information about  COVID-19, Immunodeficiency and School Attendance for parents and carers, to guide decisions about school attendance for children with primary immunodeficiency (PID) during the COVID-19 pandemic. 

The following information has also been updated, to reflect the easing of some restrictions in mid May 2020:

• COVID-19 Frequently Asked Questions (FAQ) 
• Checklist: Actions to reduce the spread of COVID-19 
• COVID-19 and Immunodeficiency Updated May 2020 (Accessed more than 94,000 times in March and April 2020)

Following the release of the ASCIA Position Statement - Specific Treatments for COVID-19 in April 2020, ASCIA wrote to the Australian government regarding potential of immune blockers in treatment of COVID-19. To view this letter and other ASCIA submissions go to www.allergy.org.au/ascia-reports#s1

Another recent addition to the ASCIA website is a link to the Royal College of Pathologists of Australasia (RCPA) Position Statement about COVID-19 testing www.allergy.org.au/members/covid-19#cd2